The rapid addition of small interfering RNA therapy to usual care after a recent ACS helps more patients achieve recommended LDL-cholesterol targets than does usual care alone, data from the VICTORION ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback